JP2014530882A5 - - Google Patents

Download PDF

Info

Publication number
JP2014530882A5
JP2014530882A5 JP2014537380A JP2014537380A JP2014530882A5 JP 2014530882 A5 JP2014530882 A5 JP 2014530882A5 JP 2014537380 A JP2014537380 A JP 2014537380A JP 2014537380 A JP2014537380 A JP 2014537380A JP 2014530882 A5 JP2014530882 A5 JP 2014530882A5
Authority
JP
Japan
Prior art keywords
optionally substituted
hydrogen
group
structural formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014537380A
Other languages
English (en)
Japanese (ja)
Other versions
JP6196224B2 (ja
JP2014530882A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/061737 external-priority patent/WO2013063149A1/en
Publication of JP2014530882A publication Critical patent/JP2014530882A/ja
Publication of JP2014530882A5 publication Critical patent/JP2014530882A5/ja
Application granted granted Critical
Publication of JP6196224B2 publication Critical patent/JP6196224B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014537380A 2011-10-24 2012-10-24 シアル酸類似体 Active JP6196224B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161550610P 2011-10-24 2011-10-24
US61/550,610 2011-10-24
PCT/US2012/061737 WO2013063149A1 (en) 2011-10-24 2012-10-24 Sialic acid analogs

Publications (3)

Publication Number Publication Date
JP2014530882A JP2014530882A (ja) 2014-11-20
JP2014530882A5 true JP2014530882A5 (enExample) 2015-09-10
JP6196224B2 JP6196224B2 (ja) 2017-09-13

Family

ID=48168447

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014537380A Active JP6196224B2 (ja) 2011-10-24 2012-10-24 シアル酸類似体

Country Status (13)

Country Link
US (5) US8840926B2 (enExample)
EP (1) EP2771348B1 (enExample)
JP (1) JP6196224B2 (enExample)
KR (1) KR102049214B1 (enExample)
CN (1) CN103974965B (enExample)
AU (1) AU2012328874B2 (enExample)
BR (1) BR112014009760B1 (enExample)
CA (1) CA2849114C (enExample)
ES (1) ES2807890T3 (enExample)
HK (1) HK1201067A1 (enExample)
IL (1) IL231714B (enExample)
MX (1) MX347541B (enExample)
WO (1) WO2013063149A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9241896B2 (en) 2008-12-19 2016-01-26 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies
CA2805222A1 (en) 2010-07-13 2012-01-19 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies
ES2807890T3 (es) 2011-10-24 2021-02-24 Ultragenyx Pharmaceutical Inc Análogos de ácido siálico
CA2862836A1 (en) * 2012-01-18 2013-07-25 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies
TW201720803A (zh) 2015-09-14 2017-06-16 超基因克斯製藥公司 唾液酸或其鹽或溶劑合物之晶型
WO2024173797A1 (en) * 2023-02-17 2024-08-22 Ultragenyx Pharmaceutical Inc. Crystalline forms of sialic acid derivatives and methods for their use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6168418A (ja) 1984-09-11 1986-04-08 Kanto Ishi Pharma Co Ltd 去痰薬
JPS63139193A (ja) * 1986-11-28 1988-06-10 Mect Corp シアル酸誘導体1,7−ラクトン
US6156544A (en) 1993-06-09 2000-12-05 Glaxo Group Limited Process for the preparation of N-acetylneuraminic acid
EP0820305A2 (en) 1995-04-04 1998-01-28 Wound Healing of Oklahoma Cancer treatment by photodynamic therapy, in combination with an immunoadjuvant
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
EP1070725B9 (en) 1998-04-10 2011-02-23 Mitsubishi Chemical Corporation Solid dispersion containing sialic acid derivative
KR20030006721A (ko) 2001-07-14 2003-01-23 삼성전자 주식회사 리소그라피 시스템 및 이를 이용한 레티클 표면의 파티클제거방법
ATE503498T1 (de) 2002-06-21 2011-04-15 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
US7238677B2 (en) 2003-03-28 2007-07-03 Kimberly-Clark Worldwide, Inc. Prevention of urogenital infections
JP2007517776A (ja) * 2003-12-09 2007-07-05 スフェリックス, インコーポレイテッド カテコール官能基を有する生体接着性ポリマー
KR101202607B1 (ko) 2005-03-03 2012-11-20 마나테크 인코포레이티드 영양 보조제의 조절된 방출을 위한 방법 및 조성물
US20100226855A1 (en) * 2006-03-02 2010-09-09 Spherics, Inc. Rate-Controlled Oral Dosage Formulations
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
CA2680842C (en) 2007-05-31 2015-11-24 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health N-acetyl mannosamine or derivatives thereof for use in treating a kidney disorder in a mammal
US20090081249A1 (en) 2007-08-27 2009-03-26 Massachusetts Institute Of Technology Bi-Functional Polymer-Attached Inhibitors of Influenza Virus
US8524772B2 (en) 2008-05-09 2013-09-03 Tiara Pharmaceuticals, Inc. Controlled release of N-acetylcysteine (NAC) for reduction of systemic and/or vascular inflammation
KR101116864B1 (ko) 2008-08-01 2012-02-29 주식회사 베네비오 고지혈증, 지방간 또는 비만의 예방 또는 치료용 조성물
US20100160363A1 (en) 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
US9241896B2 (en) 2008-12-19 2016-01-26 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies
US20100159001A1 (en) 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
JP5626734B2 (ja) 2009-05-15 2014-11-19 公益財団法人ヒューマンサイエンス振興財団 Gneタンパク質の機能低下に起因する疾患の治療用医薬剤、食品組成物
CA2805222A1 (en) 2010-07-13 2012-01-19 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies
ES2807890T3 (es) 2011-10-24 2021-02-24 Ultragenyx Pharmaceutical Inc Análogos de ácido siálico
CA2862836A1 (en) 2012-01-18 2013-07-25 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies
KR102646509B1 (ko) 2015-01-28 2024-03-11 교와 핫꼬 바이오 가부시키가이샤 N-아세틸노이라민산암모늄염·무수화물의 결정 및 그 제조 방법
TW201720803A (zh) 2015-09-14 2017-06-16 超基因克斯製藥公司 唾液酸或其鹽或溶劑合物之晶型

Similar Documents

Publication Publication Date Title
KR102666477B1 (ko) 글루타민 유사체의 프로드럭
CN110382508B (zh) 用于抑制精氨酸酶活性的组合物和方法
JP2014530882A5 (enExample)
ES2694328T3 (es) Composición acuosa líquida
CN113423685A (zh) 整合应激通路的前药调节剂
AR064304A1 (es) Formulaciones de ansamicina y sus metodos de uso
RU2012108874A (ru) Композиции, содержащие расщепляемые ферментами опиоидные пролекарства с модифицированным кетоном и их дополнительные ингибиторы
WO2019110773A1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
JP2025090725A (ja) 官能化シクロオクテンを調製するためのプロセス
EP3740229A1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2019110837A1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
JP2019503356A5 (enExample)
JPWO2016136641A1 (ja) 生理活性物質結合ブロック共重合体
JP2018527360A (ja) 修飾された細胞毒とその治療的使用
JP7376694B2 (ja) 再生可能資源に由来するポリマーおよび組成物
JP2021534162A (ja) 癌を処置する方法に用いられるコンジュゲート
ES2884123T3 (es) Formulaciones de inhibidores de xantina oxidasa
BR112020011484A2 (pt) composições na forma de uma solução aquática injetável compreendendo glucagon humano e um co-poliaminoácido
JP2016536372A5 (enExample)
EP4076420A1 (en) Compounds for the treatment of bacterial infections and potentiation of antibiotics
KR20220005554A (ko) 전구약물 화합물
EP3378495B1 (en) Composition comprising novel glutamic acid derivative and block copolymer, and use thereof
JP7504088B2 (ja) 医学的障害の治療のための一酸化炭素プロドラッグ
JP7506660B2 (ja) デンドリマー製剤
ITMI20120121A1 (it) Nuovi composti antitumorali